Pay in 4 interest-free payments of $5.09 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
100% disease incidence in 15 days Flexible endpoints, including histopathology, PASI and Arthritis scoring, and qPCR Proven reproducibility across multiple treatment modality studies Whether you're evaluating JAK inhibitors, biologics, or novel immunomodulators, our PsA model is optimized for screening, biomarker discovery, and combination therapy testing
Our approach focuses on improving metabolism, gut health, hormone balance, insulin sensitivity, body composition, and mitochondrial function so patients can maintain their results with more energy, fewer cravings, and better long-term health
An infusion treatment is more powerful than oral administration
External resources New England Journal of Medicine: Retatrutide Phase 2 Trial for Obesity PMC: Comparative Efficacy of Tirzepatide vs Retatrutide Network Meta-Analysis Nature Medicine: Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease U.S
For semaglutide at 2.4mg (the Wegovy dose), that number was 68%
US$ 20.89
US$ 26.43
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
US$ 29.09
